121 related articles for article (PubMed ID: 29852247)
21. Targeted hyperactivation of AKT through inhibition of ectopic expressed SHIP1 induces cell death in colon carcinoma cells and derived metastases.
Ehm PAH; Linnebacher M; Block A; Rehbach C; Jücker M
Cell Signal; 2023 Aug; 108():110720. PubMed ID: 37207939
[TBL] [Abstract][Full Text] [Related]
22. SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model.
Ehm P; Rietow R; Wegner W; Bußmann L; Kriegs M; Dierck K; Horn S; Streichert T; Horstmann M; Jücker M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443832
[TBL] [Abstract][Full Text] [Related]
23. Functional interaction of the Ras effector RASSF5 with the tyrosine kinase Lck: critical role in nucleocytoplasmic transport and cell cycle regulation.
Kumari G; Singhal PK; Suryaraja R; Mahalingam S
J Mol Biol; 2010 Mar; 397(1):89-109. PubMed ID: 20064523
[TBL] [Abstract][Full Text] [Related]
24. Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
Arregi I; Falces J; Olazabal-Herrero A; Alonso-Mariño M; Taneva SG; Rodríguez JA; Urbaneja MA; Bañuelos S
PLoS One; 2015; 10(6):e0130610. PubMed ID: 26091065
[TBL] [Abstract][Full Text] [Related]
25. Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.
Vanderwinden JM; Wang D; Paternotte N; Mignon S; Isozaki K; Erneux C
Cell Signal; 2006 May; 18(5):661-9. PubMed ID: 15990278
[TBL] [Abstract][Full Text] [Related]
26. Mutation analysis of SHIP gene in acute leukemia.
Luo JM; Liu ZL; Hao HL; Wang FX; Dong ZR; Ohno R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Aug; 12(4):420-6. PubMed ID: 15363123
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival.
Pal Singh S; de Bruijn MJW; Velaso Gago da Graça C; Corneth OBJ; Rip J; Stadhouders R; Meijers RWJ; Schurmans S; Kerr WG; Ter Burg J; Eldering E; Langerak AW; Pillai SY; Hendriks RW
J Immunol; 2020 Jan; 204(2):360-374. PubMed ID: 31836657
[TBL] [Abstract][Full Text] [Related]
28. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
29. SHIP1 and its role for innate immune regulation-Novel targets for immunotherapy.
Yeoh WJ; Krebs P
Eur J Immunol; 2023 Dec; 53(12):e2350446. PubMed ID: 37742135
[TBL] [Abstract][Full Text] [Related]
30. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
[TBL] [Abstract][Full Text] [Related]
31. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
32. Membrane localization of Src homology 2-containing inositol 5'-phosphatase 2 via Shc association is required for the negative regulation of insulin signaling in Rat1 fibroblasts overexpressing insulin receptors.
Ishihara H; Sasaoka T; Ishiki M; Wada T; Hori H; Kagawa S; Kobayashi M
Mol Endocrinol; 2002 Oct; 16(10):2371-81. PubMed ID: 12351701
[TBL] [Abstract][Full Text] [Related]
33. The Functional Roles of the Src Homology 2 Domain-Containing Inositol 5-Phosphatases SHIP1 and SHIP2 in the Pathogenesis of Human Diseases.
Müller SM; Jücker M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791291
[TBL] [Abstract][Full Text] [Related]
34. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
[TBL] [Abstract][Full Text] [Related]
35. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Zhang J; An X; Han Y; Ma R; Yang K; Zhang L; Chi J; Li W; Llobet-Navas D; Xu Y; Jiang Y
Cell Death Dis; 2016 Sep; 7(9):e2358. PubMed ID: 27584795
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
38. SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/β-catenin/Id2 axis.
Iyer S; Viernes DR; Chisholm JD; Margulies BS; Kerr WG
Stem Cells Dev; 2014 Oct; 23(19):2336-51. PubMed ID: 24857423
[TBL] [Abstract][Full Text] [Related]
39. Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia.
Hunter MG; Jacob A; O'donnell LC; Agler A; Druhan LJ; Coggeshall KM; Avalos BR
J Immunol; 2004 Oct; 173(8):5036-45. PubMed ID: 15470047
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.
Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H
Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
